Literature DB >> 10576665

Evaluation of seven tumour markers in pleural fluid for the diagnosis of malignant effusions.

M Miédougé1, P Rouzaud, G Salama, M C Pujazon, C Vincent, M A Mauduyt, J Reyre, P Carles, G Serre.   

Abstract

Carcinoembryonic antigen (CEA), carbohydrate antigens 15-3, 19-9 and 72-4 (CA 15-3, CA 19-9 and CA 72-4), cytokeratin 19 fragments (CYFRA 21-1), neuron-specific enolase (NSE) and squamous cell carcinoma antigen (SCC) were evaluated in pleural fluid for the diagnosis of malignant effusions. With a specificity of 99%, determined in a series of 121 benign effusions, the best individual diagnostic sensitivities in the whole series of 215 malignant effusions or in the subgroup of adenocarcinomas were observed with CEA, CA 15-3 and CA 72-4. As expected, a high sensitivity was obtained with SCC in squamous cell carcinomas and with NSE in small-cell lung carcinomas. CYFRA and/or CA 15-3 were frequently increased in mesotheliomas. Discriminant analysis showed that the optimal combination for diagnosis of non-lymphomatous malignant effusions was CEA + CA 15-3 + CYFRA + NSE: sensitivity of 94.4% with an overall specificity of 95%. In malignant effusions with a negative cytology, 83.9% were diagnosed using this association. The association CYFRA + NSE + SCC was able to discriminate adenocarcinomas from small-cell lung cancers. Regarding their sensitivity and their complementarity, CEA, CA 15-3, CYFRA 21-1, NSE and SCC appear to be very useful to improve the diagnosis of malignant pleural effusions.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10576665      PMCID: PMC2362942          DOI: 10.1038/sj.bjc.6690807

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  39 in total

Review 1.  The diagnostic and therapeutic utility of thoracoscopy. A review.

Authors:  R J Harris; M S Kavuru; T W Rice; T J Kirby
Journal:  Chest       Date:  1995-09       Impact factor: 9.410

Review 2.  CA 72-4 serum marker--a new tool in the management of carcinoma patients.

Authors:  F Guadagni; M Roselli; M Cosimelli; P Ferroni; A Spila; F Cavaliere; V Casaldi; G Wappner; M R Abbolito; J W Greiner
Journal:  Cancer Invest       Date:  1995       Impact factor: 2.176

3.  Carcinoembryonic antigen levels in benign and malignant pleural effusions.

Authors:  R A Rittgers; M S Loewenstein; A E Feinerman; H Z Kupchik; B R Marcel; R S Koff; N Zamcheck
Journal:  Ann Intern Med       Date:  1978-05       Impact factor: 25.391

Review 4.  Clinical tumour markers in lung cancer.

Authors:  J Niklinski; M Furman
Journal:  Eur J Cancer Prev       Date:  1995-04       Impact factor: 2.497

5.  Cyfra 21-1. A new potential tumor marker for squamous cell carcinoma of head and neck.

Authors:  I Doweck; M Barak; E Greenberg; N Uri; J Kellner; M Lurie; N Gruener
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1995-02

6.  Clinical evaluation of CYFRA 21-1 in malignant pleural fluids.

Authors:  H Satoh; M Sumi; H Yagyu; H Ishikawa; T Suyama; T Naitoh; T Saitoh; S Hasegawa
Journal:  Oncology       Date:  1995 May-Jun       Impact factor: 2.935

Review 7.  Diagnosis and management of malignant pleural effusions.

Authors:  K N Fenton; J D Richardson
Journal:  Am J Surg       Date:  1995-07       Impact factor: 2.565

8.  Simultaneous enzyme immunoassay of carcinoembryonic antigen in pleural effusion and serum.

Authors:  P P Asseo; G D Tracopoulos
Journal:  Am J Clin Pathol       Date:  1982-01       Impact factor: 2.493

9.  Continuing increase in mesothelioma mortality in Britain.

Authors:  J Peto; J T Hodgson; F E Matthews; J R Jones
Journal:  Lancet       Date:  1995-03-04       Impact factor: 79.321

10.  Clinical evaluation of seven tumour markers in lung cancer diagnosis: can any combination improve the results?

Authors:  M Plebani; D Basso; F Navaglia; M De Paoli; A Tommasini; A Cipriani
Journal:  Br J Cancer       Date:  1995-07       Impact factor: 7.640

View more
  24 in total

1.  Utility of serum tumor markers as an aid in the differential diagnosis of patients with clinical suspicion of cancer and in patients with cancer of unknown primary site.

Authors:  Rafael Molina; Xavier Bosch; Josep M Auge; Xavier Filella; José M Escudero; Víctor Molina; Manel Solé; Alfonso López-Soto
Journal:  Tumour Biol       Date:  2011-12-09

2.  Pleural fluid tumour markers in malignant pleural effusion with inconclusive cytologic results.

Authors:  L Antonangelo; R K Sales; A P Corá; M M P Acencio; L R Teixeira; F S Vargas
Journal:  Curr Oncol       Date:  2015-10       Impact factor: 3.677

3.  Elevated survivin is associated with a poor response to chemotherapy and reduced survival in lung cancer with malignant pleural effusions.

Authors:  Do-Sim Park; Ki-Eun Hwang; Hyeok Shim; Byoung-Ryun Kim; Keum-Ha Choi; Seong-Hoon Park; Seok-Don Park; Eun-Taik Jeong; Hak-Ryul Kim
Journal:  Clin Exp Metastasis       Date:  2011-11-02       Impact factor: 5.150

4.  Neoplastic pericardial disease: Old and current strategies for diagnosis and management.

Authors:  Chiara Lestuzzi
Journal:  World J Cardiol       Date:  2010-09-26

5.  Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma.

Authors:  Jenette Creaney; Deborah Yeoman; Leanne K Naumoff; Michelle Hof; Amanda Segal; Arthur William Musk; Nicholas De Klerk; Nora Horick; Steven J Skates; Bruce W S Robinson
Journal:  Thorax       Date:  2007-03-13       Impact factor: 9.139

6.  Evaluation of pleural fluid survivin and XIAP for the diagnosis of malignant pleural effusion.

Authors:  Jian Li; Zhen-Nan Li; Qian-Lei Bao; Li-Ping Ge; Xiao-Qin Li; Ping Chen
Journal:  Tumour Biol       Date:  2012-06-14

7.  Diagnostic accuracy of tumour markers in serous effusions: a validation study.

Authors:  Jaume Trapé; Rafael Molina; Francesc Sant; Jesús Montesinos; Anna Arnau; Josefina Franquesa; Rosana Blavia; Esperanza Martín; Emili Marquilles; Damià Perich; Concepción Pérez; Josep Maria Roca; Montserrat Doménech; Joan López; Josep Miquel Badal
Journal:  Tumour Biol       Date:  2012-06-08

8.  Diagnostic value of mesothelin in pleural fluids: comparison with CYFRA 21-1 and CEA.

Authors:  Rosa Filiberti; Stefano Parodi; Roberta Libener; Giovanni Paolo Ivaldi; Pier Aldo Canessa; Donatella Ugolini; Barbara Bobbio; Paola Marroni
Journal:  Med Oncol       Date:  2013-03-27       Impact factor: 3.064

9.  Bradycardia alters Ca(2+) dynamics enhancing dispersion of repolarization and arrhythmia risk.

Authors:  Jong J Kim; Jan Němec; Rita Papp; Robert Strongin; Jonathan J Abramson; Guy Salama
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-01-11       Impact factor: 4.733

Review 10.  Diagnostic utility of pleural fluid carcinoembryonic antigen and CYFRA 21-1 in patients with pleural effusion: a systematic review and meta-analysis.

Authors:  Ping Gu; Gang Huang; Yumei Chen; Cuiying Zhu; Jimin Yuan; Shile Sheng
Journal:  J Clin Lab Anal       Date:  2007       Impact factor: 2.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.